Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis[1].
in vivo
Efruxifermin (0-100 mg/kg, SC, Once weekly, for 4 or 26 weeks) reduces body weight gain of Sprague Dawley rats in a dose-dependent manner[1].
Animal Model:
Male and female Sprague Dawley rats[1]
Dosage:
0, 1, 10, 30, 100 mg/kg
Administration:
Subcutaneous injection, Once weekly, for 4 or 26weeks
Result:
Significantly reduced body weight gain after 4 and 26weeks, despite increasing food intake. Markers of sympathetic activation, urinary corticosterone and ratio of adrenal-to-body weight were unchanged.
IC 50
FGF21
References
[1] Tillman EJ, et al. Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. Br J Pharmacol. 2022 Apr;179(7):1384-1394. DOI:10.1111/bph.15725
